Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

31 Aug 2011

Abstract excerpt

BACKGROUND: CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies. However, their specific contributions to the in vivo mechanism of action of CD20 immunotherapy have not been well defined. DESIGN AND METHODS: Here we studied the in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Monoclonal and Polyclonal Antibodies Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21880632
DOI: 10.3324/haematol.2011.047159

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenPMID 21880632Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.Semantic proximity Read ↗

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsSemantic proximity Read ↗

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasSemantic proximity Read ↗

A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapySemantic proximity Read ↗

Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell LinesSemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

Molecular engineering to improve antibodies' anti-lymphoma activity.Semantic proximity Read ↗

Bispecific CD20xCD40 Antibodies Achieve Multi-Lineage Modulation of Humoral and Cellular ImmunitySemantic proximity Read ↗

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancerSemantic proximity Read ↗

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.